VYGR Stock — Voyager Therapeutics Inc.: Cash, EV, Pipeline

Share price

$3.09

Market cap

$190.4M

Cash

$116.3M

Enterprise value

$74.1M

Balance sheet

Cash	$116.3M
Debt	$0.0M
Net cash	$116.3M
Enterprise value	$74.1M
Basic shares	61.3M shares
Fully diluted shares	74.0M shares
Fully diluted market cap	$228.7M
Cash per share	$1.90

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading VYGR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 12 - Jul 24	VY7523	Phase 1/2	Alzheimer's Disease (AD)	—
Jun 9 - Jul 21	VY1706 Low dose	Phase 1	Alzheimer s Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

VY7523

Phase 1 · Active Modality: monoclonal antibody (IV, recombinant humanized IgG4)

Target tau

Indications

Alzheimer's disease (early AD) (Phase 1)

Catalysts

— Q4 2026

Status note Anti-tau antibody to inhibit the spread of pathological tau. Phase 1 SAD in healthy volunteers completed (acceptable safety/tolerability/immunogenicity); Phase 1 MAD in early AD patients initiated Feb 2025.

VY1706

Preclinical · Active Modality: gene therapy (TRACER capsid + vectorized siRNA)

Target tau (MAPT mRNA)

Indications

Alzheimer's disease (AD) (Preclinical)

Catalysts

— Q4 2026
— early 2027
— H2 2027

Status note Tau-silencing gene therapy: intravenously delivered TRACER capsid containing vectorized siRNA targeting tau mRNA. GLP toxicology study expected Q1 2026; IND submission anticipated Q2 2026 (after Q1 2026 Type C FDA communication); clinical trial initiation and dosing expected Q4 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	VY7523
Lead indication	Alzheimer's Disease (AD)
Lead phase	Phase 1/2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06874621	Phase 1/2	Active, not recruiting	Sponsor	Voyager Therapeutics	—	Alzheimer's Disease (AD)	—
NCT07764146	Phase 1	Recruiting	Sponsor	Voyager Therapeutics	—	Alzheimer s Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Voyager Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	427,554	-42,207	0.21%	2026-08-14
Ikarian Capital	53,063	no change	0.03%	2026-08-14
ADAR1 Capital Management	35,000	no change	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

VYGR — Voyager Therapeutics Inc.